Uses of medication: Defitelio (Defibrotide sodium) is used in order to treat adult and pediatric patients with hepatic veno-occlusive disease (VOD), also named sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction after hematopoietic stem-cell transplantation (HSCT).
Dosage: The recommended dose of defibrotide for pediatric or adult patients is 6.25 mg/kg every 6-hours administered as a 2 hour intravenous infusion. The defibrotide dose should be based on the patient’s baseline body weight. This medication should be administered at least for 21 days. In case following 21-days signs/symptoms of hepatic veno-occlusive disease have not been resolved, defibrotide uses should be continued until resolution of veno-occlusive disease or up to a maximum of 60-days.
Treatment Reactions: The most commonly reported defibrotide side effects include:
- Nosebleeds (Epistaxis)
- Abnormally Low Blood Pressure (Hypotension
Warnings and Precautions:
- The defibrotide 200mg should not be used in individuals with bleeding complications or who are taking blood thinners.
- Patients should be monitored for bleeding. Withhold or discontinue defibrotide sodium injection in case significant bleeding occurs.
- Patients should be informed that breastfeeding is not recommended during defibrotide sodium injection treatment.
- Patients with defitelio dose should be monitored for the hypersensitivity reactions, especially in case there is a history of the previous exposure.
- Use of defitelio (defibrotide sodium) should be avoided by women with childbearing potential.